Analysis of SARS-CoV-2 Spike Protein Variants with Recombinant Reporter Viruses Created from a Bacmid System

SARS-CoV-2, the causative agent of COVID-19, has spread around the world with more than 700 million cases and 6.8 million deaths. Various variants of concern (VoC) have emerged due to mutations and recombination and concurrent selection for increased viral fitness and immune evasion. The viral protein that primarily determines the pathogenicity, infectivity, and transmissibility is the Spike protein. To analyze the specific impact of variant Spike proteins on infection dynamics, we constructed SARS-CoV-2 with a uniform B.1 backbone but with alternative Spike proteins. In addition, ORF6 was replaced by EYFP as a biological safety measure, and for use of this well-established reporter. We show that namely the delta variant Spike proteins cause a distinct phenotype from the wild type (B.1, D614G) and other variants of concern. Furthermore, we demonstrate that the omicron BA.1 Spike results in lower viral loads and a less efficient spread in vitro. Finally, we utilized viruses with the two different reporters EYFP and mCherry to establish a competitive growth assay, demonstrating that most but not all Spike variant viruses were able to outcompete wild type SARS-CoV-2 B.1.

[1]  Z. Meshkat,et al.  Mutations in SARS-CoV-2 structural proteins: a global analysis , 2022, Virology journal.

[2]  William T. Harvey,et al.  SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway , 2022, Nature Microbiology.

[3]  Y. Kamatani,et al.  SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication , 2022, Communications Biology.

[4]  M. Neurath,et al.  SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells , 2022, Cells.

[5]  F. Kirchhoff,et al.  Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? , 2022, Journal of virology.

[6]  L. Poon,et al.  SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.

[7]  A. Kaneda,et al.  Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant , 2022, Nature.

[8]  C. Zheng,et al.  Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines , 2022, Journal of medical virology.

[9]  C. Sturmbauer,et al.  The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro , 2022, Virologica Sinica.

[10]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[11]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[12]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[13]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[14]  Y. Kawaoka,et al.  Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation , 2021, Nature.

[15]  M. Farzan,et al.  Mechanisms of SARS-CoV-2 entry into cells , 2021, Nature reviews. Molecular cell biology.

[16]  K. Überla,et al.  Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination , 2021, International journal of molecular sciences.

[17]  Xiaomin Zeng,et al.  Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States , 2021, Journal of medical virology.

[18]  Foad Alzoughool,et al.  New SARS-CoV-2 Variant from Jordan , 2021, Microbiology resource announcements.

[19]  P. Maes,et al.  Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations , 2021, Viruses.

[20]  H. Mouquet,et al.  SARS-CoV-2 Alpha, Beta and Delta variants display enhanced Spike-mediated Syncytia Formation , 2021, bioRxiv.

[21]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[22]  W. Doerfler,et al.  SARS‐CoV‐2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time‐course study – potential challenge for vaccines and therapies , 2021, medRxiv.

[23]  Vineet D. Menachery,et al.  Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.

[24]  S. Pongor,et al.  Different mutations in SARS-CoV-2 associate with severe and mild outcome , 2020, International Journal of Antimicrobial Agents.

[25]  W. Doerfler,et al.  Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus spreads and actively replicates in different parts of the world , 2020, Virus Research.

[26]  F. Klawonn,et al.  Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases , 2020, Journal of virology.

[27]  E. Hartenian,et al.  The molecular virology of coronaviruses , 2020, The Journal of Biological Chemistry.

[28]  R. Matyášek,et al.  Mutation Patterns of Human SARS-CoV-2 and Bat RaTG13 Coronavirus Genomes Are Strongly Biased Towards C>U Transitions, Indicating Rapid Evolution in Their Hosts , 2020, Genes.

[29]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[30]  A. Shehata,et al.  The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control , 2020, Journal of clinical medicine.

[31]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[32]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[33]  E. Decroly,et al.  One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities , 2014, Proceedings of the National Academy of Sciences.

[34]  Lisa E. Gralinski,et al.  Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear Import Block Enhances Host Transcription in Human Lung Cells , 2013, Journal of Virology.